

V^{ème} Congrès
CRIOAc
National

21 et 22 octobre 2021
à l'ENS Lyon

PRÉSENTIEL
& VIRTUEL

Persistance intracellulaire de *S. aureus* : mécanismes sous-jacents et implications cliniques.

Françoise Van Bambeke, PharmD, PhD

Pharmacologie cellulaire et moléculaire
Louvain Drug Research Institute
UCLouvain, Brussels, Belgium

www.facm.ucl.ac.be

How do bacteria protect themselves against antibiotics ?


“offensive strategy”: to develop resistance mechanisms



“defensive strategy”: to adopt ‘hidden’ mode of life



Main infections caused by *S. aureus*




Nature Reviews | Microbiology

Salgado-Pabón & Schlievert; Nat Rev Microbiol. 2014; 12:585-91


CRIOAC 2021

Intracellular survival and persistent infections

Evidence of an intracellular reservoir in osteocytes (A,B), osteoblasts (C) and bone matrix of a patient with recurrent osteomyelitis



Evidence of bacteria in osteocyte-lacuno canalicular network (A-B) and of 'Trojan horses' macrophages (C-D)



Antibiotic failure against intracellular *S. aureus*

J Antimicrob Chemother 2018; 73: 2418–2421
doi:10.1093/jac/dky205 Advance Access publication 12 June 2018

Journal of
Antimicrobial
Chemotherapy

Live intramacrophagic *Staphylococcus aureus* as a potential cause of antibiotic therapy failure: observations in an *in vivo* mouse model of prosthetic vascular material infections

Rym Boudjemaa¹, Karine Steenkeste¹, Cédric Jacqueline², Romain Briandet³, Jocelyne Caillon⁴, Virginie Le Mabecque², Pierre Tattevin^{4,5}, Marie-Pierre Fontaine-Aupart¹ and Matthieu

¹Institut des Sciences Moléculaires d'Orsay (ISMO), CNRS, Université Paris-Sud, Université Paris-Saclay, F-9143826, Université Nantes, Faculté Médecine, Nantes, France; ²Micalis Institute, INRA, AgroParisTech, Université Jouy-en-Josas, France; ³Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033 Rennes, France; ⁴Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033 Rennes, France; ⁵Service des Maladies Infectieuses et Réanimation Médicale, CHU Rennes, 35033 Rennes, France

Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often?

J Ciampolini and K G Harding

Postgrad Med J 2000 76: 479-483

BRIEF REPORTS • CID 2001:32 (1 June) • 1643

Intracellular Persistence of *Staphylococcus aureus* Small-Colony Variants within Keratinocytes: A Cause for Antibiotic Treatment Failure in a Patient with Darier's Disease

Christof von Eiff,¹ Karsten Becker,¹ Dieter Metzke,² Gabriele Lubritz,¹ Johannes Hockmann,² Thomas Schwarz,² and Georg Peters¹

¹Institute of Medical Microbiology and ²Department of Dermatology, Westfälische Wilhelms-Universität Münster, Münster, Germany

Journal of Antimicrobial Chemotherapy (2004) 53, 167–173
DOI: 10.1093/jac/dkh076
Advance Access publication 16 January 2004

Antibiotic-induced persistence of cytotoxic *Staphylococcus aureus* in non-phagocytic cells

Oleg Krut, Herdis Sommer and Martin Krönke*

JAC

frontiers
in Immunology

Mechanisms of Antibiotic Failure During *Staphylococcus aureus* Osteomyelitis

Brittney D. Gimza¹ and James E. Cassat^{1,2,3,4,5*}

MINI REVIEW
published: 12 February 2021
doi: 10.3389/fimmu.2021.638085




J Antimicrob Chemother 2016; 71: 438–448
doi:10.1093/jac/dkv371 Advance Access publication 20 November 2015

Staphylococcus aureus develops increased resistance to antibiotics by forming dynamic small colony variants during chronic osteomyelitis

L. Tuchscher^{1*†}, C. A. Kreis^{2†}, V. Hoerr^{1,3†}, L. Flint⁴, M. Hachmeister⁴, J. Geraci¹, S. Bremer-Streck⁵, M. Kiehntopf⁵, E. Medina⁶, M. Kribus⁷, M. Raschke², M. Pletz⁸, G. Peters⁴ and B. Löffler^{1,9}

Antimicrobial
Chemotherapy


PK/PD parameters and intracellular activity





Carryn et al, *Infect Dis Clin North Am* 2003; 17:615-34

CRIOAC 2021


In vitro model of intracellular infection



Intracellular vs extracellular activity of oxacillin





Poor response to antibiotics: resistance, tolerance, or persistence ?




Brauner et al., Nat Rev Microbiol. 2016; 14:320-30.

Persisters and antibiotics




Following bacterial multiplication at the single cell level and in real time



Roostalu et al., BMC Microbiol. 2008; 8:68.


Application to *S. aureus* planktonic cultures

O/N induction
TET 125 ng/mL → Entry into exponential phase → STOP TET → Fluorescence : +1h, +2h, +3h...





Growth rate

- 28.5 min / generation
- 30.3 min / generation (CFU method)



Application to intracellular *S. aureus*



w/o
antibiotic
(gentamicin 5xMIC)



Inoculum actively dividing inside the cell

Application to intracellular *S. aureus*


w/o
antibiotic
(gentamicin 5xMIC)




Inoculum actively dividing inside the cell

2 MIC



Oxacillin



Clarithromycin





Moxifloxacin



Peyrusson et al, Nat. Comm. 2020; 11:2200

Application to intracellular *S. aureus*

w/o
antibiotic
(gentamicin 5xMIC)





Antibiotic pressure



2 MIC

50 MIC



Oxacillin




Clarithromycin



Moxifloxacin





Fully homogenous and non-dividing population



Peyrusson et al, Nat. Comm. 2020; 11:2200

Application to intracellular *S. aureus*

w/o
antibiotic
(gentamicin 5xMIC)





Antibiotic pressure



2 MIC

50 MIC




Oxacillin




Clarithromycin



Moxifloxacin





Non dividing bacteria persist inside the cells




Cell sorting and transcriptomic analysis

Transcriptomic analysis: global view





Transcriptomic analysis: more details




Transcriptomic analysis: more details


dysregulated but active protein synthesis



Protein machinery activated
AA-tRNA synthetases silenced



Reduced but still active
de novo protein synthesis




ATP level
maintained

Transcriptomic analysis: more details


Reorientation of central metabolic flux

- carbon source shift between glucose and lactose
- Respiration resembling that observed in anaerobiosis.
- oxidative phosphorylation repressed to the benefit of D-lactate fermentation




Transcriptomic analysis: more details


Multidrug tolerance



Persister level defined by exposure to the first antibiotic



Intracellular persisters: a global view



Intracellular persisters: clinical implications


- Intracellular bacteria can remain 'dormant' inside eukaryotic cells
- Dormancy is favored by stressful conditions (antibiotic pressure, e.g.)
- Dormancy is associated to the activation of a global stress response
 - Dormant bacteria are 'multidrug tolerant'
 - Exposure to one drug makes bacteria non-responsive to other classes of drugs
- Dormancy is reversible when the stress is relieved
 - A possible reason for recurrence of the infection ?
- If deeply dormant, persisters do not grow on agar plates
 - How to detect them in biological samples ?




What about clinical isolates ?

Relative persister fraction to the fluoroquinolone moxifloxacin in a collection of clinical isolates

(a) Kill curve of a typical persister assay







(b) Relative persister fraction vs. MXF MIC




- All resistant isolates have a high relative persister fraction
- Most susceptible isolates have a low relative persister fraction

Does persistence prepare for resistance?



- Persistence accelerates the selection of resistance
- Persistence and resistance are acquired together

Persisters character to predict intracellular tolerance



Isolates with higher relative persister fraction are less responsive to moxifloxacin intracellularly

Intracellular persisters: clinical implications

- Intracellular bacteria can remain 'dormant' inside eukaryotic cells
- Dormancy is favored by stressful conditions (antibiotic pressure, e.g.)
- Dormancy is associated to the activation of a global stress response
 - Dormant bacteria are 'multidrug tolerant'
 - Exposure to one drug makes bacteria non-responsive to other classes of drugs
- Dormancy is reversible when the stress is relieved
 - A possible reason for recurrence of the infection ?
- If deeply dormant, persisters do not grow on agar plates
 - How to detect them in biological samples ?
- Clinical isolates differ by the fraction of persisters in their populations
 - Is there a link with the risk of clinical failure ?
- Activation of stress in persisters favors selection of resistance
 - Another reason to see resistance increase when dealing with chronic infections ?



Still more questions than answers



Acknowledgments

